

# A P S Hungin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10382845/publications.pdf>

Version: 2024-02-01

26  
papers

3,442  
citations

361413  
20  
h-index

552781  
26  
g-index

26  
all docs

26  
docs citations

26  
times ranked

3321  
citing authors

#	ARTICLE	IF	CITATIONS
1	Systematic review: probiotics in the management of lower gastrointestinal symptoms – an updated evidence-based international consensus. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1054-1070.	3.7	101
2	Prevalence, symptom patterns and management of episodic diarrhoea in the community: a population-based survey in 11 countries. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 586-595.	3.7	9
3	World Gastroenterology Organisation Global Guidelines Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 704-713.	2.2	90
4	Irritable bowel syndrome: an integrated explanatory model for clinical practice. <i>Neurogastroenterology and Motility</i> , 2015, 27, 750-763.	3.0	22
5	Systematic review: the perceptions, diagnosis and management of irritable bowel syndrome in primary care - A Rome Foundation Working Team Report. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1133-1145.	3.7	40
6	Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 864-886.	3.7	168
7	Symptoms in patients on long-term proton pump inhibitors: prevalence and predictors. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 431-439.	3.7	28
8	Systematic review: frequency and reasons for consultation for gastro-oesophageal reflux disease and dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 331-342.	3.7	60
9	<i>Helicobacter pylori</i> eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 1297-1303.	3.7	10
10	Patients' explanatory models for irritable bowel syndrome: symptoms and treatment more important than explaining aetiology. <i>Family Practice</i> , 2008, 26, 40-47.	1.9	45
11	GPs' explanatory models for irritable bowel syndrome: a mismatch with patient models?. <i>Family Practice</i> , 2008, 26, 34-39.	1.9	33
12	<i>Helicobacter pylori</i> eradication in long-term proton pump inhibitor users in primary care: a randomized-controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 585-592.	3.7	14
13	Medication beliefs among patients with inflammatory bowel disease who report low quality of life: a qualitative study. <i>BMC Gastroenterology</i> , 2007, 7, 20.	2.0	44
14	Self-help interventions in irritable bowel syndrome. <i>Gut</i> , 2006, 55, 603-604.	12.1	10
15	Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1365-1375.	3.7	413
16	Review article: gastro-oesophageal reflux disease – the health economic implications. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 20-31.	3.7	32
17	Review article: quality-of-life issues in gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 41-47.	3.7	45
18	The Fight for “Health-related Normality”™: A Qualitative Study of the Experiences of Individuals Living with Established Inflammatory Bowel Disease (IBD). <i>Journal of Health Psychology</i> , 2005, 10, 443-455.	2.3	107

#	ARTICLE	IF	CITATIONS
19	Use of Proton Pump Inhibitors: An Exploration of the Attitudes, Knowledge and Perceptions of General Practitioners. <i>Digestion</i> , 2005, 72, 212-218.	2.3	20
20	The effect of <i>Helicobacter pylori</i> and its eradication on gastrooesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 733-744.	3.7	68
21	Quality of life in patients with established inflammatory bowel disease: a UK general practice survey. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 529-535.	3.7	77
22	The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40000 subjects. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 643-650.	3.7	654
23	Dyspepsia: gaps between primary and secondary care. <i>Digestive and Liver Disease</i> , 2002, 34, 243-245.	0.9	2
24	Current concepts in the management of <i>Helicobacter pylori</i> infection – The Maastricht 2000 Consensus Report. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 167-180.	3.7	1,068
25	Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1889-1893.	3.7	30
26	Inflammatory bowel disease: epidemiology and management in an English general practice population. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 1553-1559.	3.7	252